Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses

Overview

Funding for the development of monoclonal antibodies to prevent and treat infections from specific emerging or re-emerging viruses, including Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, and Chikungunya. Targets research organizations, SMEs, and consortia advancing clinical-stage antibody candidates for epidemic or pandemic preparedness.

Who Can Apply

Legal entities established in eligible EU Member States, Horizon Europe Associated Countries, the United Kingdom, Switzerland, or the United States. Participation of SMEs, startups, and third-country partners from virus-endemic regions is encouraged. Consortia are permitted.

Funding Details

Maximum grant amount: 11,000,000 EUR per project. Funding rate and co-funding requirements are not specified.

What Is Funded

Development of prophylactic and therapeutic monoclonal antibodies (e.g., B-cell derived, hybridoma derived, or nanobodies) targeting one of the following viruses: Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, or Chikungunya. Activities include:

• Finalization of in-vitro characterization (specificity, epitope recognition, viral inactivation).
• In-vivo testing in animal models (including humanized models if available) or non-human primates if required for clinical trials.
• Assessment of Antibody-Dependent Enhancement (ADE) risk.
• GMP-compliant production of antibody batches.
• First-in-human clinical safety studies with a clear regulatory pathway for market authorization.

Technology / Maturity Requirements

Projects must target Technology Readiness Levels (TRL) 7–9, focusing on late-stage development and clinical validation.

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12T22:00:00Z

Application Process (High-Level)

Single-stage application process. Proposals must be submitted via the Funding & Tenders Portal. Clinical study details must be provided in a dedicated annex using the template available in the submission system.

Post-Award Obligations

• Engagement with regulatory bodies to ensure compliance.
• Timely reporting and dissemination of results.
• The granting authority may object to transfers of ownership or exclusive licensing of results for up to 4 years post-project.

Geographic Scope & Language

Eligible countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, United Kingdom, Switzerland, and the United States. Application language: English.

Notes

• Proposals must target only one of the specified viruses.
• Projects are expected to leverage existing research infrastructures (e.g., ISIDORe).
• Attention to biological and social factors (sex, age, ethnicity, disability) is required.
• A balanced portfolio across targeted viruses will be prioritized during evaluation.